v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
CURRENT ASSETS    
Cash
Prepaid expenses and other 9,339 81,223
Due from Sponsor 36,503
Total Current Assets 45,842 81,223
Cash and Investments held in Trust Account 6,668,522 19,901,169
TOTAL ASSETS 6,714,364 19,982,392
CURRENT LIABILITIES    
Accounts Payable 1,030,615 152,005
Loan and Transfer notes payable 465,722 12,384
Subscription Agreement loan 13,760,771
Other Current Liabilities 358,939 238,939
Total Current Liabilities 15,616,047 403,328
TOTAL LIABILITIES 15,616,047 403,328
COMMITMENTS AND CONTINGENCIES (Note 6)
REDEEMABLE ORDINARY SHARES    
Class A ordinary shares subject to possible redemption at redemption value, $0.0001 par value, 577,644 and 1,803,729 shares at redemption value of $11.54 and $ 11.03 per share on December 31, 2024 and 2023, respectively 6,668,522 19,901,169
SHAREHOLDERS’ DEFICIT    
Series A Preferred stock, par value $0.0001, 25,000,000 shares authorized, 322,059 outstanding
Additional paid-in-capital 8,802,978 10,964,930
Accumulated Deficit (24,373,902) (11,287,754)
Total shareholders’ deficit (15,570,205) (322,105)
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT 6,714,364 19,982,392
Aspire Biopharma Inc [Member]    
CURRENT ASSETS    
Cash 3,633 11,174
Prepaid Expenses 144,356 35,000
Subscriptions Receivable
Total Current Assets 147,989 46,174
TOTAL ASSETS 147,989 46,174
CURRENT LIABILITIES    
Accounts Payable 310,219 172,773
Short-term loans from shareholders 1,266,832 360,636
Other Current Liabilities 111,026 626
Total Current Liabilities 1,688,077 534,035
TOTAL LIABILITIES 1,688,077 534,035
SHAREHOLDERS’ DEFICIT    
Common stock, par value $0.00005, 750,000,000 shares authorized, 440,000,000 outstanding 22,000 22,000
Additional paid-in-capital 1,215,113 957,500
Accumulated Deficit (2,777,233) (1,467,361)
Total shareholders’ deficit (1,540,088) (487,861)
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT 147,989 46,174
Common Class A [Member]    
SHAREHOLDERS’ DEFICIT    
Common stock, par value $0.00005, 750,000,000 shares authorized, 440,000,000 outstanding 719 719
Common Class B [Member]    
SHAREHOLDERS’ DEFICIT    
Common stock, par value $0.00005, 750,000,000 shares authorized, 440,000,000 outstanding
Series A Preferred Stock [Member] | Aspire Biopharma Inc [Member]    
SHAREHOLDERS’ DEFICIT    
Series A Preferred stock, par value $0.0001, 25,000,000 shares authorized, 322,059 outstanding $ 32